Camp4 Therapeutics (CAMP) EPS (Basic) (2023 - 2026)

Camp4 Therapeutics has reported EPS (Basic) for 4 years, with the latest figure at -$0.21 in Q1 2026.

• Quarterly EPS (Basic) rose 68.86% year-over-year to -$0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.97 (up 68.22% YoY) and the FY2025 annual result came in at -$4.16, up 83.26% from the prior year.
• EPS (Basic) improved to -$0.21 in Q1 2026 per CAMP's latest filing, from -$0.32 in the prior quarter.
• Over five years, EPS (Basic) peaked at -$0.21 in Q1 2026 and troughed at -$42.65 in Q3 2024.
• A 4-year average of -$15.24 and a median of -$2.33 in 2024 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2024 and 2025: EPS (Basic) sank 37.68% in 2024, then surged 98.79% in 2025.
• Over 4 years, EPS (Basic) stood at -$32.89 in 2023, then soared by 92.91% to -$2.33 in 2024, then jumped by 86.35% to -$0.32 in 2025, then soared by 33.74% to -$0.21 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.21, -$0.32, and -$0.52 for Q1 2026, Q4 2025, and Q3 2025 respectively.